Antibody Response in Seropositive Multiple Sclerosis Patients Vaccinated with Attenuated Live Varicella Zoster Virus

Simple item page
dc.contributor.authorRoss, RT
dc.contributor.authorDawood, MR
dc.contributor.authorCheang, Mary
dc.contributor.authorNicolle, Lindsay E
dc.date.accessioned2016-06-09T17:08:25Z
dc.date.available2016-06-09T17:08:25Z
dc.date.issued1996-1-1
dc.date.updated2016-06-07T07:03:25Z
dc.description.abstractOBJECTIVE: To determine the safety and effectiveness of live attenuated varicella zoster virus (VZV) vaccine (OKA/Merck) on 50 patients with chronic progressive multiple sclerosis (MS), based on the hypothesis that VZV might be the antigen or antigen mimic of MS plus the fact that repeated high antigen doses have produced ‘antigen paralysis’ in experimental allergic encephalomyelitis mice.DESIGN: Fifty patients were randomly selected without controls. They were assessed clinically at entry and on four other occasions over 14 months. Enhanced cranial magnetic resonance imaging (MRI) was performed at entry and at six and 12 months post entry. All were vaccinated after initial assessment and again six weeks later.SETTING: All clinical and laboratory assessments were performed at the Health Sciences Centre, Winnipeg, in the out-patient department. All MRI examinations were performed at the St Boniface General Hospital, Winnipeg, Manitoba. Both are tertiary care hospitals.POPULATION STUDIED: Fifty randomly selected patients with chronic progressive MS, age 18 to 60 years, and a disability status scale of 2.0 or greater were included. Forty-five patients completed the study.INTERVENTIONS: Two vaccinations with attenuated live VZV six weeks apart.RESULTS: All patients were VZV seropositive at entry and all showed an increased antibody level following vaccination. No one was harmed by the vaccine. There may have been some changes in the MS of 15 patients.CONCLUSIONS: It may be reasonable and safe to challenge the process of MS using large doses of the immunogenic proteins of the VZV to induce ‘immune paralysis’.
dc.description.versionPeer Reviewed
dc.identifier.citationRT Ross, MR Dawood, Mary Cheang, and Lindsay E Nicolle, “Antibody Response in Seropositive Multiple Sclerosis Patients Vaccinated with Attenuated Live Varicella Zoster Virus,” Canadian Journal of Infectious Diseases, vol. 7, no. 5, pp. 303-306, 1996. doi:10.1155/1996/417061
dc.identifier.urihttp://dx.doi.org/10.1155/1996/417061
dc.identifier.urihttp://hdl.handle.net/1993/31471
dc.language.rfc3066en
dc.rightsopen accessen_US
dc.rights.holderCopyright © 1996 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.titleAntibody Response in Seropositive Multiple Sclerosis Patients Vaccinated with Attenuated Live Varicella Zoster Virus
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
CJIDMM.1996.417061.xml
Size:
14.41 KB
Format:
Extensible Markup Language
Description:
Download
Thumbnail Image
Name:
CJIDMM.1996.417061.pdf
Size:
119.21 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.24 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works